Global Partners L.P. (GLP)
NYSE NYSE Primary 
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has engaged a contract research organization to perform the world's first-ever fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study (the "Study"). Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy.
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed.
Global Partners LP Common Units (GLP) Q3 2024 Earnings Call Transcript
Global Partners LP Common Units (NYSE:GLP ) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Sean Geary - CLO & Secretary Conference Call Participants Selman Akyol - Stifel Operator Good day, everyone, and welcome to the Global Partners Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded.
Registration Is Now Open For Tribe Public's Webinar Event "Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing" Featuring Modular Medical CEO On Monday, November 11, 2024
Meet with Modular Medical CEO, Jeb Besser Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks Discover Modular Medical's Recently Announced Results from a Successful GLP-1 Proof of Concept Study SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing." The event is scheduled to begin at 8:00am pacific/11:00am eastern on Monday, November 11, 2024.
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms provides the following glucagon-like peptide-1 ("GLP-1") industry update. It is no surprise that Novo Nordisk's ("Novo") blockbuster drug, semaglutide, which is sold under the brand names Ozempic®, Wegovy®, and Rybelsus®, is the bestselling diabetes and weight loss drug in the world today.
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone -Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, announced successful results from its pre-clinical GLP-1 proof of concept study. "We are excited by the results of this pre-clinical, proof of concept study in a standard obese mouse model," stated Dr. David Maggs, M.D.
Hims & Hers Health CFO talks GLP-1s, earnings
Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, helped by a tax benefit and strong demand for GLP-1 weight-loss drugs.
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours trading after the strong Q3 results and raised outlook (~8 points higher on growth and 2 points of additional adjusted EBITDA margin). HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to direct-to-consumer models.
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating'
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-loss drugs continue to draw subscribers.
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and early sales success, Madrigal's Q3 earnings will be crucial in determining Rezdiffra's commercial viability and stock performance. The potential for Rezdiffra to achieve blockbuster status is tempered by its high cost and the emerging threat of GLP-1 agonists in the MASH market.
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the "Study"). Blood Sugar Levels (mmol/L) DehydraTECH Groups Day 7 Baseline Day 28 % Change to Day 28 Day 56 % Change to Day 56 Day 84 % Change to Day 84 A: CBD1 27.4 26.2 -4.31% 26.9 -1.90% 27.7 1.09% B: CBD2 28.4 29.2 2.73% 26.6 -6.22% 27.3 -3.76% C: CBD3 26.4 24.9 -5.99% 27.1 2.46% 27.5 3.85% D: CBD4 24.6 27.9 13.16% 26.8 8.94% 27.0 9.75% E: Rybelsus1 26.4 25.5 -3.60% 26.8 1.33% 26.8 1.59% w/SNAC F: Rybelsus2 24.9 26.8 7.70% 26.4 5.96% 27.3 9.58% w/SNAC G: Semaglutide 26.3 25.9 -1.52% 27.8 5.54% 26.9 2.13% No SNAC H: Liraglutide 26.4 25.8 -2.08% 25.2 -4.56% 23.3 -11.54% No SNAC Notes - Groups A through D were different DehydraTECH-CBD compositions - Groups E and F were reformulated Rybelsus DehydraTECH compositions - Groups G and H used pure GLP-1 drugs (semaglutide and liraglutide respectively) in DehydraTECH compositions - Recalculations led to slight changes from earlier reported data Lexaria is strongly encouraged that the DehydraTECH-liraglutide and DehydraTECH-CBD groups A and B outperformed all three of the Rybelsus® and pure semaglutide DehydraTECH composition groups regardless of whether the semaglutide had or had not been processed with the salcaprozate sodium technology known as "SNAC".
